Testosterone Therapy's heart risks under the microscope for transgender youth
NCT ID NCT04977765
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how testosterone therapy changes heart and metabolic health in transgender boys and men aged 12 to 30. Researchers will measure blood vessel function, blood pressure, and body composition over one year. The goal is to understand any risks and whether starting therapy before or after puberty makes a difference.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 90 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2021
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
EXCLUSION CRITERIA FOR TRANSGENDER AND CISGENDER INDIVIDUALS 1. Any disease affecting glucose, sex steroid, or fat metabolism such as diabetes, polycystic ovary syndrome, or clinical suspicion of insulin resistance) 2. Any medication use that may affect glucose, sex steroid, or fat metabolism such as metformin or glucocorticoids 3. Known cardiovascular disease such as hypertension or atherosclerosis 4. Raynaud's phenomenon or other vascular disease 5. BMI \> 40 kg/m2 for those aged ≥ 18 years or \> 95% percentile for age- and sex-assigned at birth in those aged \< 18 years 6. Pregnancy or lactation 7. Any condition that, in the investigator's opinion, may compromise study participation or may confound the interpretation of the study results.
- Ages
-
12 to 30 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * INCLUSION CRITERIA FOR TRANSGENDER BOYS AND TRANSGENDER MEN 1. Sex assigned female at birth and a male gender identity (i.e., transgender male) 2. Aged 12-30 years 3. Have a care provider in the Children's Wisconsin Gender Health Clinic or Froedtert Hospital Inclusion Clinic who has determined the individual meets clinical criteria to start testosterone therapy and plans to initiate this therapy 4. Naïve to testosterone or other masculinizing medical therapy 5. Cisgender girls/women and transgender boys/men of child-bearing potential (defined as having achieved menarche (first menses), excluding those who have had a hysterectomy or are on GnRH agonist therapy (puberty blockers)) must be willing to use effective birth control (which may include abstinence)) from screening visit until final study visit 6. Willing and able to give informed consent or have parent or legal guardian provide informed consent if the subject is \< 18 years of age INCLUSION CRITERIA FOR CISGENDER INDIVIDUALS 1. Gender identity concordant with sex assigned at birth (i.e., cisgender) 2. Aged 12-30 years 3. Not related to a transgender participant enrolled in the study 4. Naïve to any sex hormone or pubertal blocker therapy or, specific to cisgender girls/women only, must be ≥ 1 year from use of oral contraceptive or other contraceptive technique (intrauterine device, medroxyprogesterone injections) 5. Willing and able to give informed consent or have parent or legal guardian provide informed consent if the subject is \< 18 years of age INCLUSION CRITERIA FOR OPTIONAL NITROGLYCERIN ENDOTHELIUM-INDEPENDENT VASCULAR FUNCTION STUDY 1. Aged ≥ 18 years 2. No history of migraine headaches 3. Systolic blood pressure ≥ 110 mm Hg 4. No prior past adverse reaction to nitroglycerin 5. Has not used a PDE5 inhibitor (i.e., sildenafil, tadalafil, vardenafil) in the past 7 days Exclusion Criteria: \-
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Transgender are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does testosterone reshape the teen brain and ease headaches?
- Study seeks to improve cancer screening for transgender individuals before hysterectomy
- Freezing hope: new study aims to protect fertility in transgender youth
- New study aims to freeze ovarian tissue for transgender fertility
- Hormone therapy's hidden impact on gut bugs and heart risk revealed in new study.
- New online tool aims to support Trans/Nonbinary young adults in love and life